MarketPulse
O

$OSUR

4 articles found
3 positive
0 negative
1 neutral
Investing.comInvesting.com··Jeffrey Neal Johnson

Biodefense Boom: Co-Diagnostics Eyes National Security Contracts Amid Ebola Emergency

Co-Diagnostics surges 200%+ as WHO declares Ebola emergency, positioning the company's decentralized manufacturing network as strategic national security asset.
CODXOSURGOVXFDA approvalnational security
The Motley FoolThe Motley Fool··Motley Fool Transcribing

OraSure Charts Path to Profitability With Margin Expansion and FDA Pipeline

OraSure posts 4% Q1 revenue growth to $27.9M with gross margin expansion to 42.3%, maintaining $177M cash. Two FDA submissions expected midyear clearance with 2027 breakeven guidance.
OSURoperating lossescash position
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OraSure Appoints AI Diagnostics Expert Bertrand to Board; Settles With Activist Investor

OraSure Technologies appoints healthcare tech executive John Bertrand to board and agrees to declassify board structure following settlement with activist investor Altai Capital Management.
OSURstrategic transformationAI diagnostics
GlobeNewswire Inc.GlobeNewswire Inc.··Mordor Intelligence

Drug Screening Market Set to Double to $20.86B by 2031 Amid Tech Boom

Global drug screening market projects 16.16% CAGR growth through 2031. Chromatography and mass spectrometry lead with 44.77% share; Asia-Pacific fastest growing.
ABTTMODHRSMMNYBIO+4Asia Pacific growthpoint-of-care testing